Isofol Medical: Successfully completes second dose level in phase Ib/II study - Redeye

Redeye comments on Isofol’s update that the second dose level in its ongoing phase Ib/II study has been completed successfully, with 200 mg/m² shown to be safe and well tolerated. We view the clearance to proceed to 300 mg/m² as an important step in validating the revised dosing strategy for arfolitixorin, supported by preclinical data indicating a dose-response relationship.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129130/isofol-medical-successfully-completes-second-dose-level-in-phase-ib-ii-study?utm_source=finwire&utm_medium=RSS